Plus, news about Laverock Therapeutics, Bristol Myers Squibb, Sobi, Pliant Therapeutics, Bayer and Takeda:
INmune Bio’s Alzheimer’s disease drug fails Phase 2 study: The company was testing XPro, a TNF inhibitor, in 200 patients with ...
↧